Navigation Links
Biotechnology Thought Leader, Dr. Abbie Celniker, Joins ImaginAb Board of Directors as Chairman
Date:8/13/2012

LOS ANGELES and BOSTON, Aug. 13, 2012 /PRNewswire/ -- ImaginAb, Inc. a developer of in vivo molecular imaging agents based on its proprietary antibody fragment platform, today announced that Abbie Celniker, Ph.D. has joined the company as a Director and Chair of the Board.

"In ImaginAb's search for Board leadership, we set out to attract an industry visionary with perspective from big biopharma as well as entrepreneurial experience and we have found all of these qualities in Dr. Celniker." said Christian Behrenbruch, Ph.D., Chief Executive Officer of ImaginAb. "We are delighted to welcome Dr. Celniker to our team and look forward to her contributions as we develop our groundbreaking in vivo molecular imaging agents."

"Companion diagnostic strategies are increasingly critical to new therapeutic management strategies in the oncology and immunology space," commented Dr. Celniker. "ImaginAb's platform for re-engineering therapeutic antibody drugs into imaging agents is unique in the industry and bears great potential. ImaginAb is beginning to realize the promise of this technology by advancing its internal clinical pipeline in cancer and autoimmune diseases, as well as multiple collaborations with biopharma."

Abbie Celniker, Ph.D., is currently President and CEO of Eleven Biotherapeutics (Boston, MA) and brings more than 20 years of proven expertise in building protein discovery and development programs and biologics-focused businesses. Prior to Eleven Biotherapeutics, she led Taligen, which was acquired by Alexion Pharmaceuticals in 2011. Dr. Celniker was formerly the global head of biologics at Novartis, where she forged strategic alliances and led internal discovery and development to build the pipeline. Earlier in her career, Dr. Celniker spent more than six years at Millennium Pharmaceuticals as senior vice president, R&D strategy and operations and head of biotherapeutics and pharmaceutical sciences. She also held development roles with Wyeth BioPharma (Genetics Institute) and Genentech.

About ImaginAb
ImaginAb is redefining therapeutic management by harnessing the power of antibody technology for in vivo imaging. The company's proprietary antibody fragment platform yields actionable molecular information to guide treatment decisions in cancer and immunology. ImaginAb also collaborates with select biopharmaceutical partners to design imaging agents as companion diagnostics for therapeutic antibodies. ImaginAb's technology is positioned to deliver on the promise of personalized medicine by improving patient outcomes and reducing the cost of healthcare.

For more information, visit www.imaginab.com.


'/>"/>
SOURCE ImaginAb, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
2. Johnson & Johnson (China) Investment Ltd. Acquires Guangzhou Bioseal Biotechnology Co., Ltd.
3. TaiGen Biotechnology Out-Licensed China Rights of Novel Antibiotic, Nemonoxacin, to Zhejiang Medicine
4. Antibiotics and Biotechnology Take Center Stage at Food Dialogues Event
5. Next Generation Pharmaceutical Manufacturing Summit Pushes the Envelope of Thought-Leadership at its September Summit in London
6. TMG Health To Present Kip Piper at Thought Leadership Dinner
7. GDS Internationals Fourth Next Generation Pharmaceutical Drug Development Summit Attracts an Unprecedented Delegation of Thought Leaders
8. Nutrilys Del Mar Joins Health Forces With LAPD Underwater Dive Unit
9. Keith McCormick Joins Trovagene, Inc. as Head of Commercial Operations
10. Aethlon Medical Note: Marc Robins Joins the Aethlon Team
11. Effie Toshav Joins Fenwick - Broadens Life Sciences Service Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... -- FinancialBuzz.com News Commentary  ... Based on New Frontier Data,s sales forecasts in ... legal will generate $655 million in taxes on retail sales. Out ... such as Washington State,s 37% cannabis retail ... sales taxes that are applied on all retail sales. By 2020, ...
(Date:3/27/2017)... INVICTUS MD STRATEGIES CORP. ("Invictus MD" or the "Company") (CSE: ... to announce it has received conditional approval to list ... Exchange.  Receiving the conditional listing approval ... for Invictus-MD. Some of which include: ... ("AB Labs"), a Licensed Producer under the Access to ...
(Date:3/27/2017)... March 27, 2017  BERG, a biopharmaceutical ... biological research approach, today announced that the ... discovery of new data using a cold-induced ... fat metabolism. Joslin Diabetes Center led the ... platform for analysis of samples.  The findings ...
Breaking Medicine Technology:
(Date:3/27/2017)... ... March 27, 2017 , ... ... management program at Women’s Excellence will help patients lose weight and keep it ... The specialists at Women's Excellence will measure BMI, body fat composition, and ...
(Date:3/27/2017)... San Mateo, CA (PRWEB) , ... March 27, 2017 , ... Janet Schloz is still ... one of the best days I’ve had in a long time,” she said. , She ... a lot of money that I never thought I would have to help my students.” ...
(Date:3/27/2017)... ... March 27, 2017 , ... ?Grow Healthy Vending ... the pending litigation between itself and 1800 Vending DBA Healthy You Vending. (Civil ... am thrilled to announce that we have now reached a settlement agreement regarding ...
(Date:3/26/2017)... Columbus, Ohio (PRWEB) , ... March 26, 2017 ... ... 100 doctors worldwide to receive the RealSelf 100 Award, a prestigious award honoring ... elective cosmetic procedures and to find and connect with doctors and clinics. , ...
(Date:3/24/2017)... ... March 24, 2017 , ... Mediaplanet today ... conversation on the current obstacles facing infection prevention and offer strategies for the ... by these infections. , The print component of “Fighting Infection” is distributed ...
Breaking Medicine News(10 mins):